4.3 Manufacturers, Wholesalers, 503B Outsourcing Facilities & 3PLs

4.3 Manufacturers, Wholesalers, 503B Outsourcing Facilities & 3PLs

Quick Answer: In Tennessee, wholesale drug distributors and manufacturers are licensed annually under Tenn. Comp. R. & Regs. Chapter 1140-09, requiring designated representatives, background checks, and strict climate and physical security controls. Third-Party Logistics Providers (3PLs) are regulated under Chapter 1140-16; they provide warehousing and logistics without taking ownership or title to drug products. Under the federal Drug Supply Chain Security Act (DSCSA), all supply chain trading partners—including dispensers—must capture and maintain the "3 Ts" (Transaction Information, Transaction History, and Transaction Statement) for at least six (6) years. If a product is identified as suspect, it must be quarantined immediately; if determined to be illegitimate, the entity must notify the FDA (via Form 3911) and all immediate trading partners within twenty-four (24) hours. Section 503B Outsourcing Facilities compound sterile medications for office use without patient-specific prescriptions, but must register with the FDA, hold Tennessee licensure, and strictly comply with Current Good Manufacturing Practice (cGMP).

---

1. Wholesale Distributor & Manufacturer Licensure in Tennessee: Chapter 1140-09

The wholesale distribution of prescription drugs and devices is governed in Tennessee under T.C.A. Title 63, Chapter 10, T.C.A. Title 53, and Tenn. Comp. R. & Regs. Chapter 1140-09.

• Definition of Wholesale Distribution: The distribution of prescription drugs to persons other than a consumer or patient. It excludes intracompany sales, transfer between group purchasing organizations, emergency medical reasons (such as a pharmacy transferring temporary stock to alleviate an acute shortage), or the sale of minimal drug quantities by a retail pharmacy to a licensed practitioner for office use (provided gross dollar volume does not exceed 5% of total prescription drug sales under federal PDMA / Tennessee rules).
• Annual Licensure Requirement: In contrast to pharmacy practice site licenses (which renew biennially), licenses for manufacturers, wholesale distributors, and repackagers in Tennessee expire and must be renewed annually.
• Out-of-State Licensing: Any manufacturer or wholesale distributor located outside Tennessee that ships, distributes, or delivers prescription drugs or medical devices into Tennessee must obtain an active non-resident wholesale distributor or manufacturer license from the Tennessee Board prior to conducting business.
• Facility and Security Standards:
  • Wholesale facilities must maintain secure perimeter fencing, commercial burglar alarms, electronic key-card access, and surveillance cameras covering all entry and loading dock areas.
  • Temperature, humidity, and environmental parameters must be monitored continuously with electronic dataloggers to ensure compliance with USP compendial storage standards.
  • Quarantine Area: The facility must provide a physically separate, clearly designated quarantine area for the storage of drugs that are outdated, damaged, deteriorated, misbranded, adulterated, or in opened/tampered containers awaiting disposition.
• Designated Representative Mandate:
  • Each wholesale distributor must designate a primary Designated Representative responsible for operations.
  • The designated representative must be at least 21 years of age, have a minimum of 3 years of verifiable full-time management or supervisory experience in wholesale distribution, submit to a state and federal fingerprint-based criminal background check, and be employed full-time in a managerial role at the licensed facility.

---

2. Third-Party Logistics Providers (3PLs): Chapter 1140-16

With the passage of the federal Drug Quality and Security Act (DQSA), state and federal laws modernized the oversight of entities that store and transport pharmaceuticals without taking legal title.

Legal Definition and Regulatory Scope

Under federal law (21 U.S.C. § 360eee) and Tenn. Comp. R. & Regs. Chapter 1140-16:

• A Third-Party Logistics Provider (3PL) is an entity that provides or coordinates warehousing, distribution, or other logistics services of a product in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of a product, but does not take ownership of the product, nor have responsibility to direct the sale or disposition of the product.
• Separate Licensure Required: A 3PL operating in Tennessee, or shipping products into Tennessee, must hold a distinct 3PL license issued by the Tennessee Board of Pharmacy under Chapter 1140-16. A 3PL cannot operate under a general wholesale distributor permit.
• Standards of Compliance: 3PLs must maintain comprehensive inventory tracking systems, maintain strict environmental controls (temperature and humidity mapping), enforce background checks on key personnel, and provide complete audit logs to state and federal investigators upon request.

---

3. Section 503A Traditional Compounding vs. Section 503B Outsourcing Facilities

The Drug Quality and Security Act (DQSA) of 2013 amended the Federal Food, Drug, and Cosmetic Act by dividing pharmaceutical compounding into two distinct statutory tracks: Section 503A and Section 503B. Understanding this distinction is a major focus of modern MPJE testing.

┌─────────────────────────────────────────────────────────────────────────────┐
│                 503A TRADITIONAL PHARMACY vs. 503B OUTSOURCING FACILITY     │
├────────────────────────────┬────────────────────────────────────────────────┤
│ Feature                    │ Section 503A Traditional │ Section 503B Outsourcing    │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Primary Regulation         │ State Board of Pharmacy  │ FDA & State Board   │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Prescription Mandate       │ MUST have patient-       │ Bulk compounding    │
│                            │ specific prescription    │ for "office use"    │
│                            │ (or limited anticipation)│ WITHOUT Rx allowed  │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Quality / CGMP Standards   │ USP <795> & <797>        │ Full FDA cGMP       │
│                            │ (State standards)        │ (21 CFR 210/211)    │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ FDA Pre-market Approval    │ Exempt (No NDA/ANDA)     │ Exempt (No NDA/ANDA)│
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Adequate Directions (502f) │ Exempt                   │ Exempt              │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Inspection Authority       │ State Board of Pharmacy  │ FDA Risk-Based &    │
│                            │ (Routine state audits)   │ State Investigators │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Adverse Event Reporting    │ State-level CQI logs     │ MANDATORY to FDA    │
│                            │                          │ within 15 days      │
├────────────────────────────┼──────────────────────────┼─────────────────────┤
│ Labeling Requirements      │ State prescription label │ Detailed lot, cGMP, │
│                            │ standards                │ "Not for Resale",   │
│                            │                          │ "Compounded Drug"   │
└────────────────────────────┴──────────────────────────┴─────────────────────┘

Section 503A: Traditional Compounding Pharmacies

• Governed primarily by the Tennessee Board of Pharmacy.
• Compounding must be pursuant to a valid, patient-specific prescription order (or in limited quantities in anticipation of receiving prescriptions based on an established history of local prescribing).
• Prohibition on Office Use: A traditional 503A pharmacy in Tennessee cannot compound sterile drugs for "office use" to be administered by a physician to unknown, unspecified future patients without individual patient prescriptions.
• Standards: Must comply with USP General Chapters <795> (non-sterile), <797> (sterile), and <800> (hazardous drugs). Exempt from federal cGMP requirements and FDA pre-market approval.

Section 503B: Outsourcing Facilities

• Created directly in response to the 2012 New England Compounding Center (NECC) tragedy.
• An outsourcing facility is a geographic facility that is engaged in the compounding of sterile drugs, has elected to register with the FDA as an outsourcing facility under Section 503B, and holds a sterile manufacturer / outsourcing facility license from the Tennessee Board of Pharmacy.
• Bulk Compounding Authorized: Can compound sterile preparations in large batches and distribute them to hospitals, surgery centers, and clinics for "office use" without patient-specific prescriptions.
• Strict cGMP Mandate: Unlike 503A pharmacies, 503B facilities are strictly subject to FDA Current Good Manufacturing Practices (cGMP) codified in 21 CFR Parts 210 and 211. This requires validated cleanroom environments, continuous air velocity monitoring, media fills, end-product batch sterility testing, endotoxin testing, and stability testing for beyond-use dating.
• FDA Regulatory Oversight: Subject to rigorous, unannounced risk-based inspections by FDA federal investigators.
• Mandatory Reporting: Must submit semi-annual compounding reports to the FDA identifying all drugs compounded, active ingredients, dosage forms, and strengths. Must report all serious adverse events to the FDA within 15 calendar days.

---

4. Drug Supply Chain Security Act (DSCSA) & The "3 Ts"

Title II of the DQSA established the Drug Supply Chain Security Act (DSCSA), codified at 21 U.S.C. § 360eee et seq. The DSCSA establishes an interoperable, electronic, package-level tracing system to identify and trace prescription drugs as they are distributed across the United States.

The "3 Ts" of Product Tracing

For every commercial change of ownership of a prescription drug, the transferring trading partner must provide, and the receiving partner (including a retail or hospital dispenser) must capture and maintain, the "3 Ts":

1. Transaction Information (TI):
   • Proprietary (brand) or established (generic) name of the product.
   • Strength and dosage form.
   • National Drug Code (NDC).
   • Container size and number of containers.
   • Lot number assigned by the manufacturer.
   • Date of the transaction and date of the shipment.
   • Business name and address of the person/entity from whom ownership is being transferred and to whom ownership is being transferred.
2. Transaction History (TH):
   • An electronic statement comprising the cumulative Transaction Information (TI) for each prior transaction going back to the original manufacturer. (Note: As enhanced package-level electronic interoperability becomes universal, TH is electronically verifiable through serialized data exchanges).
3. Transaction Statement (TS):
   • An affirmative, legally binding statement of compliance certifying that the transferring trading partner:
     • Is authorized (licensed) under the DSCSA.
     • Received the product from an authorized trading partner.
     • Received Transaction Information (TI) and Transaction Statement (TS) from the prior owner.
     • Did not knowingly ship a suspect or illegitimate product.
     • Has systems and processes in place to comply with verification requirements.
     • Did not knowingly provide false transaction information.

Mandatory 6-Year Record Retention Standard

• All records related to the 3 Ts (TI, TH, and TS) must be retained by dispensers (pharmacies) and wholesale distributors for at least six (6) years from the date of the transaction.
• Critical MPJE Distinction: While standard Tennessee pharmacy prescription records and DEA controlled substance records must be retained for two (2) years, DSCSA product tracing documentation must be preserved for six (6) years! Confusing these two retention timelines is a classic MPJE distractor.

Serialized Product Identifiers

The DSCSA mandates that manufacturers and repackagers encode a standardized 2D data matrix barcode on each individual saleable package. This barcode contains four serialized data points:

1. National Drug Code (NDC).
2. Unique Serial Number (up to 20 alphanumeric characters).
3. Lot Number.
4. Expiration Date.

---

5. Suspect Product vs. Illegitimate Product Protocols

Dispensers and wholesalers must maintain written standard operating procedures (SOPs) for identifying, quarantining, and resolving products that pose a risk to public safety.

┌─────────────────────────────────────────────────────────────────────────────┐
│                 SUSPECT PRODUCT vs. ILLEGITIMATE PRODUCT                    │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Legal Classification     │ Statutory Definition & Mandatory Action          │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ SUSPECT PRODUCT          │ Reason to believe product is counterfeit,        │
│                          │ diverted, stolen, fraudulent, or adulterated.    │
│                          │ ──► IMMEDIATELY QUARANTINE                       │
│                          │ ──► Conduct internal investigation               │
│                          │ ──► Verify 3 Ts & serialized package identifier  │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ ILLEGITIMATE PRODUCT     │ Credible evidence confirms product is            │
│                          │ counterfeit, diverted, stolen, or adulterated.   │
│                          │ ──► MAINTAIN STRICT PHYSICAL QUARANTINE          │
│                          │ ──► NOTIFY FDA via Form 3911 WITHIN 24 HOURS     │
│                          │ ──► NOTIFY Immediate Trading Partners WITHIN 24H │
│                          │ ──► Sample retention & secure disposition        │
└──────────────────────────┴──────────────────────────────────────────────────┘

Protocol for Suspect Product

• Statutory Standard: A product is deemed "suspect" when there is reason to believe that the product:
  • Is counterfeit, diverted, or stolen;
  • Is intentionally adulterated such that the product would result in serious adverse health consequences or death;
  • Is the subject of a fraudulent transaction; or
  • Appears otherwise unfit for distribution such that the product would be reasonably likely to cause serious adverse health consequences.
• Mandatory Dispensary Action:
  1. Immediately isolate and physically quarantine the product in a designated, locked holding area away from active dispensing inventory.
  2. Promptly conduct an internal investigation in coordination with manufacturers and trading partners.
  3. Validate the serialized product identifier (serial number and lot) and verify all 3 Ts records.
  4. If the investigation clears the product (false alarm), document the findings, release the product back into active stock, and retain the investigation records for 6 years.

Protocol for Illegitimate Product & FDA Form 3911

• Statutory Standard: A product is deemed "illegitimate" when credible evidence demonstrates that the product is counterfeit, diverted, stolen, intentionally adulterated, or fraudulent.
• Mandatory Actions & Strict 24-Hour Notification Mandate:
  1. Maintain Quarantine: Ensure the product remains strictly quarantined; it cannot be returned to the general supply chain or dispensed.
  2. FDA Electronic Notification (Form 3911): The entity must notify the FDA electronically using FDA Form 3911 (Drug Notification) within twenty-four (24) hours of making the determination!
  3. Trading Partner Notification: The entity must notify all immediate trading partners (the wholesaler or dispenser from whom it was received or to whom it was sold) within twenty-four (24) hours.
  4. Coordination with FDA: Work with the FDA and law enforcement for product testing, retention of representative samples, and formal disposition/destruction.

---

6. DEA Suspicious Order Monitoring (SOM) Framework

Under the federal Controlled Substances Act (21 CFR § 1301.74(b)) and the federal SUPPORT for Patients and Communities Act, wholesale distributors, manufacturers, and reverse distributors must design and operate an automated Suspicious Order Monitoring (SOM) system.

Defining Suspicious Orders

Under DEA regulations, suspicious orders include:

1. Orders of unusual size (e.g., an independent rural retail pharmacy ordering 20,000 oxycodone 30 mg tablets when its historical monthly average is 500 tablets).
2. Orders deviating substantially from a normal pattern (e.g., sudden shifts from non-controlled medications to high-potency opioids and benzodiazepines).
3. Orders of unusual frequency (e.g., placing daily orders for maximum allowable thresholds).

Distributor Obligations & Centralized Reporting

• Automated Algorithmic Screening: Distributors must employ computer algorithms to halt orders that breach established statistical ordering thresholds.
• Mandatory Reporting to DEA: When a suspicious order is identified, the distributor must report the order immediately to the DEA via the centralized Suspicious Orders Report System (SORS) database.
• Suspension of Delivery: The distributor cannot ship the flagged suspicious order unless the distributor conducts thorough due diligence and affirmatively verifies that the order is legitimate and will not be diverted. Shipping suspicious orders without due diligence results in massive civil penalties, criminal prosecution, and revocation of the distributor's DEA registration.

---

7. Comparative Matrix: Supply Chain Entities, Quality Regimes & Tracing

---

8. Practical Exam Scenarios

Scenario 1: Compounding for Clinic "Office Use"

Case: A local orthopedic surgical clinic contacts Dr. Adams, the PIC of an independent community compounding pharmacy (licensed as a 503A practice site in Franklin, TN). The clinic requests 200 vials of preservative-free bupivacaine/triamcinolone injection for general in-office joint injections, without providing individual patient names or prescriptions. Dr. Adams agrees to prepare and sell the batch directly to the clinic labeled "For Office Use Only." Legal Analysis: Dr. Adams and the pharmacy are violating federal law and Tennessee Board of Pharmacy rules. Under Section 503A of the FDCA and Tennessee compounding standards, a traditional 503A pharmacy can only compound sterile medications pursuant to a valid, patient-specific prescription order. Preparing bulk sterile injectables for clinic "office use" without patient-specific prescriptions is restricted exclusively to FDA-registered Section 503B Outsourcing Facilities operating under cGMP. Dr. Adams' dispensing constitutes the unlawful distribution of an unapproved new drug, rendering the medication adulterated and misbranded under federal law.

Scenario 2: Counterfeit Packaging Discovery & FDA Form 3911 Reporting

Case: On Monday morning at 9:00 AM, a hospital pharmacy technician in Chattanooga opens a case of a high-cost oncology monoclonal antibody. The technician notices that the manufacturer's security hologram is missing, the font on the vials is blurred, and the lot number does not match the outer shipper carton. By 11:00 AM, the hospital's clinical specialist contacts the manufacturer and confirms that the lot number is completely counterfeit. Legal Analysis: The hospital has established credible evidence that the medication is an "illegitimate product" under the DSCSA (21 U.S.C. § 360eee). The pharmacy must: (1) immediately maintain the product in physical quarantine; and (2) notify the FDA electronically using FDA Form 3911 and notify the supplying wholesale trading partner within twenty-four (24) hours of making the determination (i.e., by 11:00 AM on Tuesday). Furthermore, all internal investigation records and DSCSA data must be retained for at least 6 years.